Annji Pharmaceutical Co (ROCO:7754) Risk Assessment

View and export this data going back to 2024. Start your Free Trial

What is Annji Pharmaceutical Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Annji Pharmaceutical Co is: No Data: Cannot be evaluated.

Competitive Comparison of Annji Pharmaceutical Co's Risk Assessment

For the Biotechnology subindustry, Annji Pharmaceutical Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annji Pharmaceutical Co's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Annji Pharmaceutical Co's Risk Assessment falls into.

Annji Pharmaceutical Co (ROCO:7754) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Annji Pharmaceutical Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Annji Pharmaceutical Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Annji Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annji Pharmaceutical Co Ltd (ROCO:7754) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011

Website

https://www.ajpharm.com

Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.

Annji Pharmaceutical Co Headlines

No Headlines